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Abstract
Background: Named entity recognition (NER) is an important first step for text mining the
biomedical literature. Evaluating the performance of biomedical NER systems is impossible without
a standardized test corpus. The annotation of such a corpus for gene/protein name NER is a difficult
process due to the complexity of gene/protein names. We describe the construction and
annotation of GENETAG, a corpus of 20K MEDLINE® sentences for gene/protein NER. 15K
GENETAG sentences were used for the BioCreAtIvE Task 1A Competition.
Results: To ensure heterogeneity of the corpus, MEDLINE sentences were first scored for term
similarity to documents with known gene names, and 10K high- and 10K low-scoring sentences
were chosen at random. The original 20K sentences were run through a gene/protein name tagger,
and the results were modified manually to reflect a wide definition of gene/protein names subject
to a specificity constraint, a rule that required the tagged entities to refer to specific entities. Each
sentence in GENETAG was annotated with acceptable alternatives to the gene/protein names it
contained, allowing for partial matching with semantic constraints. Semantic constraints are rules
requiring the tagged entity to contain its true meaning in the sentence context. Application of these
constraints results in a more meaningful measure of the performance of an NER system than
unrestricted partial matching.
Conclusion: The annotation of GENETAG required intricate manual judgments by annotators
which hindered tagging consistency. The data were pre-segmented into words, to provide indices
supporting comparison of system responses to the "gold standard". However, character-based
indices would have been more robust than word-based indices. GENETAG Train, Test and Round1
data and ancillary programs are freely available at ftp://ftp.ncbi.nlm.nih.gov/pub/tanabe/
GENETAG.tar.gz.  A newer version of GENETAG-05, will be released later this year.
Background
The automatic identification of gene and protein names in
the MEDLINE® database of literature citations is a chal-
lenging named entity recognition (NER) task. Biomedical
NER has been an active research area for some time. Sys-
tems capable of high performance on this task are desira-
from A critical assessment of text mining methods in molecular biology
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ble because NER precedes other tasks including
information extraction and text mining. The apparent
simplicity of the gene/protein NER task conceals its inher-
ent complexity stemming from an often unconventional
and ambiguous genetic nomenclature.
We have previously developed AbGene, a gene/protein
name tagger trained on MEDLINE abstracts using a com-
bination of statistical and rule-based strategies. Due to the
difficulty of manually evaluating AbGene results, we
needed to create a tagged corpus for evaluating the per-
formance of AbGene applied to full text articles. The
GENIA corpus version 3.0 contains a total of 93,293 bio-
logical terms annotated by two domain experts [1]. How-
ever, it was not suitable for our purposes because we ran
AbGene on unrestricted text, and the GENIA corpus is
restricted to text retrieved using the search terms human,
blood cell and transcription factor. Additionally, the entities
in GENIA are allowed to be generic, whereas AbGene was
designed to extract specific gene/protein names only.
One fundamental problem in corpus annotation is the
definition of what constitutes an entity to be tagged. For
example, the MUC-7 Named Entity Task to identify organ-
izations, persons and locations in text necessitated the
lengthy MUC-7 Named Entity Task Definition, which
specify the rules for annotating each entity [2]. The follow-
ing excerpts from the MUC-7 Named Entity Task Defini-
tion exemplify the complexity of the annotation process:
A.1.1 Entity-expressions that modify non-entities
Entity names used as modifiers in complex NPs that are
not proper names are to be tagged when it is clear to the
annotator from context or the annotator's knowledge of
the world that the name is that of an organization, person,
or location.
A.1.3 Entity-strings embedded in entity-Expressions
In some cases, multi-word strings that are proper names
will contain entity name substrings; such strings are not
decomposable; therefore, the substrings are not to be
tagged. (See A.1.2 re special cases involving prenominal
modifiers of person identifiers.)
A.1.6.2 The definite article in an alias
When a definite article is commonly associated with an
alias, it also must be tagged.
<ENAMEX TYPE="PERSON">The Godfather</ENAMEX>
However, the scoring program ignores a certain list of pre-
modifiers as specified in section 3.3 which may make the
scoring in some of these cases more lenient than this rule
implies. The scorer does *not* ignore those premodifiers
within quotation marks such as inside the tags in A.1.6.1
above.
The developers of the GENIA corpus followed a less exact-
ing annotation strategy that did not allow determiners,
ordinals nor cardinals to appear in tagged entities, but left
qualifiers, including adjectives, as somewhat arbitrary
judgement calls [1].
For GENETAG annotation, we chose a wide definition of
a gene/protein entity, but added a constraint that requires
the tagged entity to refer to a specific entity, hereafter
called the "specificity constraint." The specificity con-
straint allows for entities like tat dna sequence but not dna
sequence. No distinctions were made between genes, pro-
teins, RNA, domains, complexes, sequences, fusion pro-
teins, etc. A finer-grained definition is possible, for
example, proteins, genes and RNA can be distinguished as
separate entities using machine learning with 78–84%
accuracy [3]. However, most biomedical NER systems do
not make these distinctions. Also, Hatzivassiloglou et al.
found that their machine learning algorithms did not per-
form well against a human baseline model, suggesting
that either the humans were correct, and the decreased
performance was due to classification difficulty, or the
machine-learned programs were penalized for being more
consistent than humans. Because humans agreed only
about 77% of the time on protein, gene and RNA labels,
the inclusion of these distinctions in a gold standard
would be an additional source of significant ambiguity.
Our decision to include domains, complexes, subunits
and promoters (but only if they refer to a specific gene/
protein) was based on gene names in GenBank. (Domain:
A discrete portion of a protein with its own function. The
combination of domains in a single protein determines its
overall function. [Source: DOE Genome Glossary
http:www.ornl.gov/sci/techresources/Human_Genome/
glos sary/index.shtml];  Complex: In chemistry, the rela-
tively stable combination of two or more compounds into
a larger molecule without covalent binding; Subunit: A
single biopolymer separated from a larger multimeric
structure  [Source: Stedman's Online Medical Dictionary,
27th Edition http://www.stedmans.com]; Promoter: a seg-
ment of DNA located at the "front" end of a gene, which
provides a site where the enzymes in involved in the tran-
scription process can bind on to a DNA molecule, and
initiate transcription [Source: Genomics Online Terms http:/
/www.biojudiciary.org/glossary/index.asp?flt=p)
For example, the name in (1) suggests that a particular
subunit is considered to be a gene entity because it is asso-
ciated with a GenBank sequence. Similarly, (2) shows that
promoters can be considered to be gene-sequence-related
entities. Our specificity constraint requires the presence ofBMC Bioinformatics 2005, 6:S3
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Sf3b4 in (1) and transaldolase in (2). Thus, subunit 4 alone
in (1) and promoter region alone in (2) would not be true
positives.
1) Sf3b4, splicing factor 3b, subunit 4
2) Mus musculus transaldolase gene, promoter region
Some exceptions to the specificity constraint were incor-
porated into the annotation scheme due to their appear-
ance in GenBank:
3) bHLH transcription factor mRNA
4) Xenopus laevis similar to POU domain gene
By defining a gene based on gene names in GenBank, but
requiring only a partial match, we have addressed the fact
that gene names in text are often not exact matches to
their official names. This is an advantage of manually
annotating a corpus instead of relying on lists of official
gene names for a gold standard – each entity in each con-
text can be expertly evaluated and revised if necessary. The
above examples illustrate some of the motivation behind
the compilation of a list acceptable alternative gene/pro-
tein names. In (1), many systems would probably not
extract the entire entity, and would be penalized. A more
flexible evaluation would be possible if it were recognized
that "Sf3b4" and "Sf3b4, splicing factor 3b," are accepta-
ble alternatives to the full form. It would also allow sys-
tems to delete the organism name in (2), as well as the fact
that it refers to the promoter region. The acceptable alter-
natives are always subject to the specificity constraint so
that the important parts of gene/protein names are pre-
served. In addition to the specificity constraint described
here, we applied semantic constraints to define gene/pro-
tein entities.
Semantic constraints are rules stating that the tagged
entity must contain its true meaning in the sentence con-
text. These constraints were geared towards multiword
entities, especially ones that include numbers, letters and
acronyms. For example, the name in (5) requires rabies
because RIG implies that the gene mentioned in this sen-
tence refers to the rabies immunoglobulin, and not just any
immunoglobulin. In (6), the word receptor is necessary to
differentiate IGG receptor from IGG, an important seman-
tic distinction. In (7), the number 1 is needed to accu-
rately describe a specific type of tumor necrosis factor,
although tumor necrosis factor alone might be adequate in
a different context.
5) rabies immunoglobulin (RIG)
6) IGG receptor
7) Tumor necrosis factor 1
GENETAG consists of 20K sentences that have been run
through AbGene [4] and manually annotated with gene
and protein names (via a web interface) by experts in bio-
chemistry, genetics and molecular biology. It is a hetero-
geneous set of sentences that contains many true positive
gene names, and also many non-gene entities that are
morphologically similar to gene names. There are approx-
imately 24K instances of gene/protein names in the 20K
sentences. 15K of the sentences were used in BioCreAtIvE-
2004 Task 1A [5]. Previous biomedical NER systems were
difficult to compare because there were few large gene-
tagged corpora available. Although GENETAG was not
originally intended to be widely distributed, in releasing
the corpus to the larger biomedical NER community
through the BioCreAtIvE Evaluation, we hoped to stimu-
late interest in this area and provide a means to evaluate
multiple systems on unrestricted biomedical text.
GENETAG annotation guidelines were designed to define
true positive gene/protein names in terms of their specifi-
city and semantics. Each sentence in GENETAG is anno-
tated with acceptable alternatives to the gene/protein
names it contains, allowing for partial matching with
semantic constraints, a more meaningful measure of the
performance of an NER system than unrestricted partial
matching. This paper provides some background on the
corpus including 1) sentence selection, 2) definition of a
gene/protein name, 3) tokenization and partial matching
and 4) tagging consistency.
Implementation
We used Naïve Bayesian learning to predict the likelihood
that a MEDLINE document contains a gene/protein name
[6-8]. The classifier was trained on a set of MEDLINE doc-
uments containing known gene/protein names against
the rest of MEDLINE. High-scoring documents almost
always contain gene/protein names, and low-scoring doc-
uments often contain no gene/protein names. We found
that we could apply our classifier to sentences as well as
documents. Since we required the corpus to contain both
true gene/protein names and non-gene-related entities,
we randomly selected 10K high- and 10K low-scoring
MEDLINE sentences as the basis for our corpus. The Baye-
sian classifier is implemented in C++. The 20K sentences
were run through AbGene, and the resulting gene/protein
tags were manually transformed by three domain experts
in genetics, biochemistry and molecular biology. Annota-
tion was done using a web interface, using check boxes
under words to indicate gene/protein names for the gold
standard, and manual entry of partial match alternative
names and indices (see Figure 1). A flexible evaluation
program was implemented in Perl.BMC Bioinformatics 2005, 6:S3
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GENETAG Annotation Method Figure 1
GENETAG Annotation Method. The annotator selects the boxes under each word in a gene/protein name and presses 
the "Mark" button. The resulting name is highlighted in yellow, and the marked fragments are shown in the bottom left frame. 
The annotator selects allowable alternatives from this list and presses "Save". Alternatives beyond the scope of the original 
highlighted name are input manually (along with their indices) into the text entry box. The lower right frame shows all the 
alternatives to the original name, along with their indices and the sentence number. A link to the abstract is provided for con-
textual clues.BMC Bioinformatics 2005, 6:S3
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Results
GENETAG contains 20K sentences tagged with gene/pro-
tein names (see Table 1 for some corpus statistics). An
additional file of acceptable alternatives to the tagged
gene/protein names is available. The gold standard com-
bined with the acceptable alternatives allows for flexible
scoring using meaningful  partial matching. The flexible
evaluation program checks first for the gold standard ver-
sion of the name, then checks for each of the available
alternatives to the gold standard version of the name.
Word indices ensure that specificity and semantic con-
straints are met for sentences that contain overlapping,
repeated and/or nested names.
Discussion
Tokenization is problematic in gene/protein name NER
because punctuation cannot be globally removed to make
processing straightforward. Gene and protein names often
contain hyphens, parentheses, brackets, and other types
of punctuation, thus using Penn Treebank style tokeniza-
tion [9], where most punctuation is split from neighbor-
ing words, is not ideal. The Penn Treebank contains
"subtleties" for hyphens and dashes, similarly, our origi-
nal tokenization was based on rules that usually apply to
gene and protein names: 1) do not split on hyphens (Myc-
2, c-Cbl, POU-domain proteins), 2) do not split on single
quotation marks (5'-rearranged myb,  5'-GCACGTTTT-3',
Marek's disease virus serotype 2 glycoprotein M), 3) do not
split on commas (Na+,K(+)-ATPase), and 4) do not split
on parentheses and brackets ((GST)-Lyn fusion). AbGene
applies these tokenization rules to terms that resemble
gene names (phrases with commas embedded in words,
matching parentheses appearing in the same word, aster-
isks in the middle of words, embedded semicolons, etc.),
and not to other phrases (phrases with commas not
embedded in words, parentheses not appearing in the
same word, asterisks outside of words, semicolons outside
of words, etc.), resulting in inconsistent tokenization.
Some parentheses are surrounded by spaces, others are
not, dependent on whether the phrase resembled a gene
name or not. The corpus was later re-tokenized automati-
cally (after annotation was completed) to be closer to the
Penn Treebank style, with the exception of hyphenations
and single quotation marks. Although the second tokeni-
zation is more consistent than the original tokenization, it
introduces some awkward spaces into gene names, for
example in (8), (9) and (10).
8) human alpha 1, 2-mannosidase
9) (IL) -1beta
10) D. melanogaster Surf-3 / rpL7a
Exact matching to a gold standard corpus is too stringent
for evaluation purposes since there is not always one and
only one correct answer for each entity. However, unre-
stricted partial matching is suboptimal because it allows
unsuitable fragments with insertions and deletions to
count as true positives. Canonical form matching is not
possible for many organisms given current resources. In
GENETAG we allowed partial matching, but the matches
were subject to the specificity and semantic constraints
described earlier for defining a gene/protein name. Partial
matching with semantic constraints allows for acceptable
gene/protein name alternatives like p53, p53 genes, p53
protein, but rejects fragments like all p53 genes, p53 patients
and -1beta. Our flexible matching strategy entails that the
tokenization of the gold standard corpus and test set be
identical since it relies on the location of each word in the
sentence. A positional approach is necessary because often
one sentence contains many gene/protein names, includ-
ing overlapping, repeated and/or nested names. To illus-
trate this problem, suppose an NER system identified the
following gene in sentence fragment (11): TGF-beta1. It
would be impossible to know which of the two instances
of TGF-beta1 was actually extracted by the system without
sentence indices. In (12), a similar ambiguity exists if an
NER program were to extract the gene list: TNF, Toll-like
receptor. Does TNF refer to human tumor necrosis factor or
TNF receptor 1? Did the system extract part of Toll-like
receptor 2 or Toll-like receptor 4? The exact location of gene/
protein names in a sentence is essential for debugging
NER programs based on contextual clues, for example, in
(11) the first instance of TGF-beta1 is preceded by stimulat-
ing, and the second instance has a more generic context.
Table 1: GENETAG corpus statistics The 20K sentences were split into four subsets called Train, Test, Round1 and Round2.
Train Test Round1 Round 2 Total
Number of Sentences 7,500 2,500 5,000 5,000 20,000
Number of Words 204,195 68,043 137,586 137,977 547,801
Number of Tagged Genes = G 8,935 2,987 5,949 6,125 23,996
Total Number of Alternative Forms of Gene Names in G 6,583 2,158 4,275 4,505 17,531
Number of Gene Names in G with Alternative Forms = N 4,675 1,522 3,057 3,186 12,440
Average Number of Alternatives per Gene Name in N 1.66 1.67 1.62 1.65 1.65BMC Bioinformatics 2005, 6:S3
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The requirement that the gold standard and test sets have
the same tokenization is disadvantageous. However, posi-
tional information is necessary for further natural lan-
guage processing (NLP), since it affects both syntactic
structure and semantic interpretation.
11) Inflammation has been inferred to play a major role
in stimulating TGF-beta1 production since high concen-
trations of TGF-beta1 have been found in the lungs of
patients with various diffuse inflammatory lung diseases.
12) RIP3-deficient cells showed normal sensitivity to a
variety of apoptotic stimuli and were indistinguishable
from wild-type cells in their ability to activate NF-kappa B
signaling in response to the following: human tumor
necrosis factor (TNF), which selectively engages mouse
TNF receptor 1 ; cross-linking of the B- or T-cell antigen
receptors; peptidoglycan, which activates Toll-like recep-
tor 2 ; and lipopolysaccharide (LPS), which stimulates
Toll-like receptor 4.
GENETAG was annotated manually, thus the tags
assigned were judgment calls by human annotators.
Annotation guidelines were established, however, many
grey areas soon appeared for which no generalized rules
were formulated. In particular, names containing con-
junctions were difficult to tag. In (13), it seems excessive
to require an NER program to recognize the entire frag-
ment, however, 3 alone is not a valid gene name.
13) src homology 2 and 3
Due to the specificity constraint, we were unable to for-
mulate a syntactic rule for handling conjunctions system-
atically. For example, the underlined terms satisfying the
specificity constraint in examples (14), (15) and (16)
occur arbitrarily to the left or right of the word "or."
Accepted alternatives for (14) were: ICP34 . 5, ICP34 . 5
promoters, mutant ICP34 . 5 promoters, wild-type or mutant
ICP34 . 5, and mutant ICP34 . 5. Accepted alternatives for
(15) were: Rab1B, Rab1B, -5, Rab1B, -5, -7, and Rab1B, -5,
-7, -8. Accepted alternatives for (16) were: beta, or gamma
PKC, gamma PKC, and PKC.
14) wild-type or mutant ICP34 . 5 promoters
15) Rab1B, -5, -7, -8, or -11A
16) alpha, beta, or gamma PKC
Adjoining gene/protein names also presented a challenge
during annotation, since gene/protein name boundaries
are not immediately obvious in these instances. It is an
intricate task to assign the exact boundaries in (17) and
(18), even for domain experts, and in (19) it is unclear
whether E2, RAD5 and UBC2 are stand-alone synonyms
or parts of a complex or fusion protein. Similarly, it is dif-
ficult even for experts to determine how many separate
entities are denoted in (20). Often the sentence context,
and sometimes the entire abstract context, is inadequate
for the correct determination to be made, so other
resources (books, websites, and full text articles) must be
consulted. This time-consuming lookup step necessitates
a trade-off between tagging consistency and annotation
time.
17) stress-activated protein kinase-Jun N-terminal kinase
18) tumor necrosis factor (TNF) receptor-associated factor
(TRAF)
19) E2 RAD5 (UBC2)
20) LAZ3/BCL6 BTB/POZ
Even in unambiguous cases, tagging inconsistencies can
appear due to human error. In particular, the partial
matching alternatives are sensitive to inconsistencies
because the names and indices were input manually into
a text box on an annotation web page (see Fig. 1).
Conclusions
We have described the GENETAG corpus of tagged gene/
protein names in MEDLINE text which was used in Bio-
CreAtIvE Task 1A. The corpus was designed to contain
both true and false positive gene/protein names in a vari-
ety of contexts. Gene/protein names are defined widely,
but are subject to specificity and semantic constraints. The
annotation guidelines were designed with the goal of
allowing flexible matching to the gold standard, while
retaining the true meaning of the tagged entities. Arbitrary
partial matches not corresponding to a complete and
meaningful entity fail to meet the annotation guidelines
and are scored as false positives and/or false negatives. A
more detailed definition of a gene/protein name, as well
as additional annotation rules, could improve interanno-
tator agreement and help solve some of the tagging incon-
sistencies. Subtle tokenization issues exist in the corpus,
and the requirement that the gold standard and test sets
have the same tokenization is disadvantageous (see dis-
cussion in [10]). However, a positional approach is neces-
sary to disambiguate sentences which contain adjoined,
repeated and/or nested gene names, and for future NLP
applications. A more robust approach would use charac-
ter-based rather than word-based indices to allow for a
wider diversity of tokenization.
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